AL Amyloidosis Treatment: Can AstraZeneca Turn Anselamimab's Trial Disappointment into a Practice-Changing Advance?

AstraZeneca, a prominent pharmaceutical company, has recently encountered a significant setback in its efforts to develop treatments for rare diseases, specifically concerning an experimental drug named anselamimab. This drug